SAN RAMON, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical
company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full
spectrum of cancer care, today announced that the primary analysis from the Company’s GALE-301 Phase 1/2a clinical trial will be
presented at the upcoming American Society of Clinical Oncology Annual Meeting 2016, taking place June 3-7, 2016 in Chicago,
IL. Details of the poster presentation are as follows:
| Poster #: |
Board #399 |
| Abstract #: |
5576 – the abstract can be found on the conference website here
|
| Title: |
The primary analysis of a phase I/IIa dose finding trial of a folate binding protein vaccine, E39 +
GM-CSF in ovarian and endometrial cancer patients to prevent recurrence |
| Session Title: |
Gynecologic Cancer |
| Date: |
Monday, June 6, 2016 |
| Time: |
1:00 p.m. to 4:30 p.m. local time |
| Location: |
Hall A |
About GALE-301
GALE-301 is a cancer immunotherapy that consists of a peptide derived from Folate Binding Protein (FBP) combined with the immune
adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF) for the prevention of cancer recurrence in the adjuvant
setting. FBP is a well-validated therapeutic target that is highly over-expressed in ovarian, endometrial and breast cancers.
FBP is the source of immunogenic peptides that can stimulate cytotoxic T lymphocytes (CTLs) to recognize and destroy FBP-expressing
cancer cells. Enrollment has been completed in the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial in two gynecological
cancers: ovarian and endometrial adenocarcinomas (ClinicalTrials.gov Identifier: NCT01580696).
About Ovarian/Endometrial Cancers
New cases of ovarian cancer occur at an annual rate of 12.1 per 100,000 women in the U.S., with an estimated 21,290 cases for
2015. Although ovarian cancer represents about 1.3% of all cancers, it represents about 2.4% of all cancer deaths, or an estimated
14,180 deaths in 2015. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their lifetime
(2010 – 2012 data). The prevalence of ovarian cancer in the U.S. is about 192,000 women, and the five-year survivorship for
women with ovarian cancer is 45.6%.
Due to the lack of specific symptoms, the majority of ovarian cancer patients are diagnosed at later stages of the disease, with
an estimated 75% of women presenting with advanced-stage (III or IV) disease. These patients have their tumors routinely surgically
debulked to minimal residual disease, and then are treated with platinum- and/or taxane-based chemotherapy. While many patients
respond to this treatment regimen and become clinically free-of-disease, the majority of these patients will relapse.
Depending upon their level of residual disease, the risk for recurrence after completion of primary therapy ranges from 60%
to 85%. Unfortunately for these women, once the disease recurs, treatment options are limited and the disease remains
incurable.
New cases of endometrial cancer occur at an annual rate of 25.1 per 100,000 women in the U.S., with an estimated 54,870 cases
for 2015. Although endometrial cancer represents about 3.3% of all cancers, it represents about 1.7% of all cancer deaths, or an
estimated 10,170 deaths in 2015. Approximately 2.8% of women will be diagnosed with endometrial cancer at some point during their
lifetime (2010 – 2012 data). The prevalence of endometrial cancer in the U.S. is about 620,000 women, and the five-year
survivorship for women with endometrial cancer is 81.7%.
Source: National Cancer Institute Surveillance, Epidemiology, and End Results Program
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly
growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The
Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by
NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several
concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a
clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302. For more information,
visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements about the progress of the development of Galena’s product
candidates, patient enrollment in our clinical trials, as well as other statements related to the progress and timing of our
development activities, present or future licensing, collaborative or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates or that otherwise relate to future periods. These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those identified under “Risk
Factors” in Galena’s Annual Report on Form 10-K for the year ended December 31, 2015 and most recent Quarterly Reports on Form 10-Q
filed with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements. Galena does
not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that
occur after the date of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 ir@galenabiopharma.com
